HRP20080598T3 - Combination of et-743 with 5-fluorouracil pro-drugs for the treatment of cancer - Google Patents

Combination of et-743 with 5-fluorouracil pro-drugs for the treatment of cancer

Info

Publication number
HRP20080598T3
HRP20080598T3 HR20080598T HRP20080598T HRP20080598T3 HR P20080598 T3 HRP20080598 T3 HR P20080598T3 HR 20080598 T HR20080598 T HR 20080598T HR P20080598 T HRP20080598 T HR P20080598T HR P20080598 T3 HRP20080598 T3 HR P20080598T3
Authority
HR
Croatia
Prior art keywords
radical
formula
physiological conditions
under physiological
cancer
Prior art date
Application number
HR20080598T
Other languages
English (en)
Croatian (hr)
Inventor
Ellen Rybak Mary
Original Assignee
Pharma Mar
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharma Mar filed Critical Pharma Mar
Publication of HRP20080598T3 publication Critical patent/HRP20080598T3/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HR20080598T 2003-11-13 2004-11-15 Combination of et-743 with 5-fluorouracil pro-drugs for the treatment of cancer HRP20080598T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US51969003P 2003-11-13 2003-11-13
PCT/GB2004/050026 WO2005049031A1 (en) 2003-11-13 2004-11-15 Combination

Publications (1)

Publication Number Publication Date
HRP20080598T3 true HRP20080598T3 (en) 2009-01-31

Family

ID=34619369

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20080598T HRP20080598T3 (en) 2003-11-13 2004-11-15 Combination of et-743 with 5-fluorouracil pro-drugs for the treatment of cancer

Country Status (15)

Country Link
US (1) US7622458B2 (de)
EP (1) EP1689404B9 (de)
JP (1) JP2007511499A (de)
AT (1) ATE406897T1 (de)
CA (1) CA2544320A1 (de)
CY (1) CY1108629T1 (de)
DE (1) DE602004016376D1 (de)
DK (1) DK1689404T3 (de)
ES (1) ES2314470T3 (de)
HR (1) HRP20080598T3 (de)
PL (1) PL1689404T3 (de)
PT (1) PT1689404E (de)
RS (1) RS50692B (de)
SI (1) SI1689404T1 (de)
WO (1) WO2005049031A1 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY164077A (en) * 1999-05-13 2017-11-30 Pharma Mar Sa Compositions and uses of et743 for treating cancer
MXPA02011319A (es) * 2000-05-15 2003-06-06 Pharma Mar Sa Analogos antitumorales de ecteinascidina 743.
EA005564B1 (ru) * 2000-11-06 2005-04-28 Фарма Мар, С.А. Эффективные противоопухолевые лекарственные средства
GB0117402D0 (en) * 2001-07-17 2001-09-05 Pharma Mar Sa New antitumoral derivatives of et-743
GB0202544D0 (en) 2002-02-04 2002-03-20 Pharma Mar Sa The synthesis of naturally occuring ecteinascidins and related compounds
GB0312407D0 (en) * 2003-05-29 2003-07-02 Pharma Mar Sau Treatment
SI1689404T1 (sl) 2003-11-13 2009-02-28 Pharma Mar Sau Kombinacija et-743 s 5-fluorouracil pro zdravili za zdravljenje raka
CN1897949A (zh) * 2003-11-14 2007-01-17 马尔药品公司 包含使用et－743和紫杉醇来治疗癌症的联合疗法
RU2359700C2 (ru) * 2004-10-26 2009-06-27 Фарма Мар С.А., Сосьедад Униперсональ Пегилированный липосомальный доксорубицин в комбинации с эктеинасцидином 743 (ecteinescidin 743)
KR101188691B1 (ko) * 2004-10-29 2012-10-09 파르마 마르 에스.에이. 엑티나시딘 및 디사카라이드를 포함하는 제제
WO2007009245A1 (en) * 2005-07-21 2007-01-25 Nuvo Research Inc. Stabilized chlorite solutions in combination with fluoropyrimidines for cancer treatment.
GB0522082D0 (en) 2005-10-31 2005-12-07 Pharma Mar Sa Formulations
RU2325914C2 (ru) * 2006-06-15 2008-06-10 Государственное учреждение научно-исследовательский институт онкологии Томского Научного центра Сибирского отделения Российской академии медицинских наук (ГУ НИИ онкологии ТНЦ СО РАМН) Способ лечения операбельного рака молочной железы
CA2703026A1 (en) * 2007-10-19 2009-04-23 Rafael Rosell Costa Prognostic molecular markers for et-743 treatment
DK2786753T3 (en) 2010-11-12 2019-04-15 Pharma Mar Sa Combination therapy with an antitumor antibiotic
US11332480B2 (en) 2017-04-27 2022-05-17 Pharma Mar, S.A. Antitumoral compounds
WO2019155448A1 (en) * 2018-02-12 2019-08-15 Oh Do Youn Methods and combination therapy to treat biliary tract cancer
WO2021098992A1 (en) 2019-11-21 2021-05-27 Pharma Mar, S.A. Methods of treating small cell lung cancer with lurbinectedin formulations

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5089273A (en) 1986-06-09 1992-02-18 Board Of Trustees Of The University Of Illinois Ecteinascidins 729, 743, 745, 759A, 759B and 770
US5149804A (en) 1990-11-30 1992-09-22 The Board Of Trustees Of The University Of Illinois Ecteinascidins 736 and 722
US5256663A (en) 1986-06-09 1993-10-26 The Board Of Trustees Of The University Of Illinois Compositions comprising ecteinascidins and a method of treating herpes simplex virus infections therewith
DE3635711A1 (de) 1986-10-21 1988-04-28 Knoll Ag 5-nitrobenzo(de)isochinolin-1,3-dione, ihre herstellung und verwendung
FR2697752B1 (fr) 1992-11-10 1995-04-14 Rhone Poulenc Rorer Sa Compositions antitumorales contenant des dérivés du taxane.
AU671491B2 (en) * 1992-12-18 1996-08-29 F. Hoffmann-La Roche Ag N-oxycarbonyl substituted 5'-deoxy-5-fluorcytidines
US5478932A (en) 1993-12-02 1995-12-26 The Board Of Trustees Of The University Of Illinois Ecteinascidins
US20040059112A1 (en) 1994-02-18 2004-03-25 Rinehart Kenneth L. Ecteinascidins
GB9508195D0 (en) 1995-04-20 1995-06-07 Univ British Columbia Novel biologically active compounds and compositions,their use and derivation
US5721362A (en) 1996-09-18 1998-02-24 President And Fellows Of Harvard College Process for producing ecteinascidin compounds
US5985876A (en) 1997-04-15 1999-11-16 Univ Illinois Nucleophile substituted ecteinascidins and N-oxide ecteinascidins
CZ301083B6 (cs) 1998-04-06 2009-11-04 The Board Of Trustees Of The University Of Illinois Ekteinascidinová sloucenina, farmaceutický prostredek ji obsahující a její použití
KR100643092B1 (ko) 1998-05-11 2006-11-10 파르마 마르, 에스.에이. 엑테인아시딘 743의 대사산물
MY164077A (en) * 1999-05-13 2017-11-30 Pharma Mar Sa Compositions and uses of et743 for treating cancer
AR035842A1 (es) 1999-05-14 2004-07-21 Pharma Mar Sa Metodo de hemisintesis para la formacion de compuestos intermediarios y derivados y de estructuras relacionadas con la ecteinascidina y de tetrahidroisoquinolinfenoles y compuestos intermediarios de aplicacion en dicho metodo
KR100717916B1 (ko) * 2000-02-28 2007-05-11 아방티 파르마 소시에테 아노님 캄프토테신 및 피리미딘 유도체를 포함하는 암 치료용 조성물
JP5219323B2 (ja) 2000-04-12 2013-06-26 ファルマ・マール・ソシエダード・アノニマ 抗腫瘍性エクチナサイジン誘導体
US20020137663A1 (en) 2000-08-11 2002-09-26 Forman Barry M. The anti-neoplastic agent ET-743 inhibits trans activation by SXR
EA005564B1 (ru) 2000-11-06 2005-04-28 Фарма Мар, С.А. Эффективные противоопухолевые лекарственные средства
EP1360337A1 (de) 2001-02-09 2003-11-12 The Regents Of The University Of California Mitglieder der ecteinascidin familie: zusammensetzungen und methoden
GB0121285D0 (en) 2001-09-03 2001-10-24 Cancer Res Ventures Ltd Anti-cancer combinations
KR20050038578A (ko) * 2001-10-19 2005-04-27 파르마 마르, 에스.에이. 항종양성 화합물의 암치료에 있어서의 향상된 용도
US20040019027A1 (en) 2002-04-12 2004-01-29 Barry Forman Method of treating cerebrotendinous xanthomatosis
GB0312407D0 (en) 2003-05-29 2003-07-02 Pharma Mar Sau Treatment
GB0324201D0 (en) 2003-10-15 2003-11-19 Pharma Mar Sau Improved antitumoral combinations
SI1689404T1 (sl) 2003-11-13 2009-02-28 Pharma Mar Sau Kombinacija et-743 s 5-fluorouracil pro zdravili za zdravljenje raka
CN1897949A (zh) 2003-11-14 2007-01-17 马尔药品公司 包含使用et－743和紫杉醇来治疗癌症的联合疗法
GB0326486D0 (en) 2003-11-14 2003-12-17 Pharma Mar Sau Combination treatment
AU2005288696A1 (en) 2004-09-28 2006-04-06 Pharma Mar S.A., Sociedad Unipersonal Ecteinascidin compounds as anti -inflammatory agents
RU2359700C2 (ru) 2004-10-26 2009-06-27 Фарма Мар С.А., Сосьедад Униперсональ Пегилированный липосомальный доксорубицин в комбинации с эктеинасцидином 743 (ecteinescidin 743)
KR101188691B1 (ko) 2004-10-29 2012-10-09 파르마 마르 에스.에이. 엑티나시딘 및 디사카라이드를 포함하는 제제

Also Published As

Publication number Publication date
US20070190164A1 (en) 2007-08-16
PT1689404E (pt) 2008-12-15
DE602004016376D1 (de) 2008-10-16
ES2314470T3 (es) 2009-03-16
US7622458B2 (en) 2009-11-24
CA2544320A1 (en) 2005-06-02
RS50692B (sr) 2010-06-30
EP1689404B9 (de) 2009-04-22
CY1108629T1 (el) 2014-04-09
DK1689404T3 (da) 2009-01-26
JP2007511499A (ja) 2007-05-10
ATE406897T1 (de) 2008-09-15
EP1689404A1 (de) 2006-08-16
SI1689404T1 (sl) 2009-02-28
WO2005049031A1 (en) 2005-06-02
EP1689404B1 (de) 2008-09-03
PL1689404T3 (pl) 2009-02-27

Similar Documents

Publication Publication Date Title
ATE471323T1 (de) Purinderivate als antagonisten an purinergen rezeptoren
MY140528A (en) Spiroketal derivatives and their use as therapeutic agents for diabetes
MX2010013275A (es) Compuesto novedoso de uracilo o su sal que tiene actividad inhibidora de desoxiuridin trifosfatasa de humano.
WO2007125321A3 (en) Purine and deazapurine derivatives as pharmaceutical compounds
BRPI0409938A (pt) derivados de azetidinacarboxamida e seu uso em terapia
DK1678166T3 (da) Proteinkinaseinhibitorer
HUP0300393A2 (hu) C-aril glükozid SGLT2 inhibitorok és alkalmazásuk, valamint ezeket tartalmazó gyógyszerkészítmények
FI935616A0 (fi) N4-(substituerad-oxikarbonyl)-5'-deoxi-5-fluor-cytidinderivat
EA201001669A1 (ru) Замещенные пиримидин-5-карбоксамиды 281
WO2004071388A3 (en) Medicinal compounds
PL368409A1 (en) Derivatives of triazolyl-imidazopyridine and of the triazolylpurines useful as ligands of the adenosine a2a? receptor and their use as medicaments
RU2012110380A (ru) Новое производное 5-фторурацила
CR20200418A (es) Inhibidores de orginasa y sus mètodos de uso antecedentes
MX2009003927A (es) Derivado espirocetal de tioglucosa y uso del mismo como un agente terapeutico para la diabetes.
DK2040703T3 (da) Derivater af 2-benzoylimidazopyridiner, fremstilling deraf og terapeutisk anvendelse deraf
BR0112399A (pt) Análogos de ácido graxo para o tratamento de câncer
ATE279192T1 (de) Die verwendung eines benzimidazoles zur herstellung eines medikamentes zur krebsvorbeugung
MA33320B1 (fr) Derives de rifamycine
MY146939A (en) Derivatives of 7-alkynyl-1,8-naphthyridones, preparation method thereof and use of same in therapeutics
TW200744575A (en) Methods of treating epileptogenesis
ZA200700358B (en) Alkyl substituted indoloquinoxalines
MY206577A (en) Arginase inhibitors and methods of use thereof
CY1112596T1 (el) Νεες ενωσεις και χρηση αυτων
EA200700891A1 (ru) Производные пиридина, их получение и их применение в терапии
WO2004110379A3 (en) A1 adenosine receptor antagonists